Mark Ciminelli
Cardiovascular Disease · Lancaster, SCNPI 1982657003
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 94.8% of the total across 212 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 28 manufacturers, the largest accounting for just 14.6% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2021 at $1,283 and has fallen 98.6% since, to $18 in 2025. That places this record below the midpoint for cardiovascular disease clinicians in SC, where the typical reported total is $3,855.
Across 212 payments — averaging $17.86 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novartis$552
- Biotronik Inc.$382
- Astellas Pharma US Inc$289
- Amarin Pharma, Inc.$282
- Sanofi-aventis U.S. LLC$266
- AstraZeneca$185
- plus $2K from 22 others
Across 152 payments — averaging $221.34 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Elutia, Inc.$17K
- Biotronik Inc.$17K
What the payments were for
- Food & beverage$3,58895%
- Education$1985%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novartis | 35 | $552 |
| Biotronik Inc. | 6 | $382 |
| Astellas Pharma US Inc | 8 | $289 |
| Amarin Pharma, Inc. | 19 | $282 |
| Sanofi-aventis U.S. LLC | 17 | $266 |
| AstraZeneca | 12 | $185 |
| Amgen | 12 | $183 |
| Boehringer Ingelheim | 10 | $183 |
| Esperion Therapeutics, Inc. | 10 | $178 |
| Merck | 12 | $173 |
| E.r. Squibb & Sons, L.L.C. | 11 | $158 |
| Johnson & Johnson | 10 | $139 |
| Bayer | 6 | $115 |
| Boston Scientific | 5 | $94 |
| Kowa Pharmaceuticals America, Inc. | 6 | $94 |
| Philips North America LLC | 3 | $70 |
| Pfizer | 5 | $64 |
| Edwards Lifesciences | 4 | $64 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 5 | $63 |
| Regeneron Healthcare Solutions, Inc. | 4 | $47 |
| Lundbeck LLC | 2 | $40 |
| Abbott | 2 | $39 |
| Arbor Pharmaceuticals, Inc. | 2 | $29 |
| Alnylam Pharmaceuticals Inc. | 1 | $27 |
| Vifor Pharma, Inc. | 1 | $24 |
| Infobionic, Inc | 2 | $18 |
| Novo Nordisk | 1 | $15 |
| Gilead | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- BioMonitor$239
- Acticor$110
- Solia$110
- Rivacor$110
- Edora$110
- BioMonitor 2$105
How this compares
$3,786 in reported general payments places this provider in the 45th percentile of 257 cardiovascular disease providers in South Carolina.
See all cardiovascular disease providers in South Carolina →
Other cardiovascular disease in Lancaster
- Robert BiedermanCharleston$775K
- Darren SidneyNorth Charleston$129K
- Priyanka BhattacharyaCharleston$107K
- Gregory SanGreenville$88K
- David McNeelyGreenville$78K
- Gregory EavesAiken$65K
- James SmithCharleston$64K
- Christopher SalmonGreenville$54K
- Ricky HendersonAnderson$52K
- Geetha PintoCharleston$51K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.